Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
Authors:
- Christopher GriffithsChristopher Griffiths
- Marjolein de Bruin-WellerMBMarjolein de Bruin-Weller
- Mette DeleuranMDMette Deleuran
- Maria Concetta FargnoliMFMaria Concetta Fargnoli
- Delphine Staumont-SalléDSDelphine Staumont-Sallé
- Chih-Ho HongCHChih-Ho Hong
- Jose Sánchez-CarazoJSJose Sánchez-Carazo
- Peter FoleyPFPeter Foley
- Seong Jun SeoSSSeong Jun Seo
- Jérôme MsihidJMJérôme Msihid
- Sonya L. CyrSCSonya L. Cyr
Open Access
- 18 June 2021
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 11 (4) , 1357-1372
Abstract
Introduction Dupilumab is approved as first-line systemic treatment for adults/adolescents with moderate-to-severe atopic dermatitis (AD) in Europe and elsewhere owing to its favourable benefit–risk profile. However, systemic non-steroidal immunosuppressants (NSISS) are often used as first-line therapy in clinical practice. Impact of prior therapy with NSISS on dupilumab’s treatment effect vs. control has not been described previously. This study assessed dupilumab’s efficacy vs. control in patients with moderate-to-severe AD, comparing treatment effect in patients with/without prior systemic NSISS therapy, in four phase 3 trials. Methods This post hoc analysis included 1553 patients randomized to placebo or dupilumab (300 mg q2w) as monotherapy for 16 weeks, or with concomitant topical corticosteroids (TCS) for 16/52 weeks, from four randomized, double-blind, placebo-controlled, phase 3 trials. Patients were stratified by prior use of systemic NSISS and dupilumab-treated patients were analysed against control groups (treated with placebo or placebo + TCS). Results Dupilumab-treated patients, regardless of prior treatment with NSISS, achieved a significantly higher percentage reduction from baseline in Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), Dermatology life Quality Index (DLQI), and Patient-Oriented Eczema Measure (POEM) vs. control; significantly more achieved EASI score ≤ 7, Peak Pruritus Numerical Rating Scale ≤ 4, POEM ≤ 7, and DLQI ≤ 5 by week 4. These rapid, significant improvements were seen with or without concomitant TCS and sustained through end-of-treatment. Conclusions Dupilumab treatment (monotherapy or + TCS) provides rapid, significant, sustained improvements in signs, symptoms, and quality of life in patients with moderate-to-severe AD compared with control, regardless of prior systemic NSISS use. Clinical Trial Registration LIBERTY AD SOLO 1: ClinicalTrials.gov identifier NCT02277743, EudraCT 2014-001198-15. LIBERTY AD SOLO 2: ClinicalTrials.gov identifier NCT02277769, EudraCT 2014-002619-40. LIBERTY AD CHRONOS: ClinicalTrials.gov identifier NCT02260986, EudraCT 2013-003254-24. LIBERTY AD CAFÉ: ClinicalTrials.gov identifier NCT02755649, EudraCT 2015-002653-35. Graphic AbstractKeywords
Funding Information
- Sanofi
- Regeneron Pharmaceuticals
This publication has 38 references indexed in Scilit:
- Atopic dermatitisThe Lancet, 2016
- The Impact of Atopic Dermatitis on Quality of LifeAnnals of Nutrition and Metabolism, 2015
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal miceProceedings of the National Academy of Sciences, 2014
- Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genesProceedings of the National Academy of Sciences, 2014
- Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic reviewJournal of Allergy and Clinical Immunology, 2014
- Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataractsJournal of the American Academy of Dermatology, 2011
- The use of cyclosporine in dermatology: Part IIJournal of the American Academy of Dermatology, 2010
- New insights into atopic dermatitisJournal of Clinical Investigation, 2004
- Cyclosporine nephrotoxicityTransplantation Proceedings, 2004